These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 16078325)

  • 1. Proposed core set of outcome measures in patients with primary Sjögren's syndrome: 5 year follow up.
    Theander E; Andersson SI; Manthorpe R; Jacobsson LT
    J Rheumatol; 2005 Aug; 32(8):1495-502. PubMed ID: 16078325
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Etanercept in Sjögren's syndrome: a twelve-week randomized, double-blind, placebo-controlled pilot clinical trial.
    Sankar V; Brennan MT; Kok MR; Leakan RA; Smith JA; Manny J; Baum BJ; Pillemer SR
    Arthritis Rheum; 2004 Jul; 50(7):2240-5. PubMed ID: 15248223
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inefficacy of infliximab in primary Sjögren's syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjögren's Syndrome (TRIPSS).
    Mariette X; Ravaud P; Steinfeld S; Baron G; Goetz J; Hachulla E; Combe B; Puéchal X; Pennec Y; Sauvezie B; Perdriger A; Hayem G; Janin A; Sibilia J
    Arthritis Rheum; 2004 Apr; 50(4):1270-6. PubMed ID: 15077311
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of primary Sjögren's syndrome with hydroxychloroquine: a retrospective, open-label study.
    Fox RI; Dixon R; Guarrasi V; Krubel S
    Lupus; 1996 Jun; 5 Suppl 1():S31-6. PubMed ID: 8803908
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rituximab treatment in patients with primary Sjögren's syndrome: an open-label phase II study.
    Pijpe J; van Imhoff GW; Spijkervet FK; Roodenburg JL; Wolbink GJ; Mansour K; Vissink A; Kallenberg CG; Bootsma H
    Arthritis Rheum; 2005 Sep; 52(9):2740-50. PubMed ID: 16142737
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mortality and causes of death in primary Sjögren's syndrome: a prospective cohort study.
    Theander E; Manthorpe R; Jacobsson LT
    Arthritis Rheum; 2004 Apr; 50(4):1262-9. PubMed ID: 15077310
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Etanercept in the treatment of patients with primary Sjögren's syndrome: a pilot study.
    Zandbelt MM; de Wilde P; van Damme P; Hoyng CB; van de Putte L; van den Hoogen F
    J Rheumatol; 2004 Jan; 31(1):96-101. PubMed ID: 14705226
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Sjögren's Syndrome Damage Index--a damage index for use in clinical trials and observational studies in primary Sjögren's syndrome.
    Barry RJ; Sutcliffe N; Isenberg DA; Price E; Goldblatt F; Adler M; Canavan A; Hamburger J; Richards A; Regan M; Gadsby K; Rigby S; Jones A; Mathew R; Mulherin D; Stevenson A; Nightingale P; Rauz S; Bowman SJ
    Rheumatology (Oxford); 2008 Aug; 47(8):1193-8. PubMed ID: 18524804
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determination of the subset of Sjogren's syndrome with articular manifestations by anticyclic citrullinated peptide antibodies.
    Iwamoto N; Kawakami A; Tamai M; Fujikawa K; Arima K; Aramaki T; Kawashiri S; Ichinose K; Kamachi M; Nakamura H; Origuchi T; Ida H; Eguchi K
    J Rheumatol; 2009 Jan; 36(1):113-5. PubMed ID: 19132785
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quality of life and psychological status in patients with primary Sjögren's syndrome and sicca symptoms without autoimmune features.
    Champey J; Corruble E; Gottenberg JE; Buhl C; Meyer T; Caudmont C; Bergé E; Pellet J; Hardy P; Mariette X
    Arthritis Rheum; 2006 Jun; 55(3):451-7. PubMed ID: 16739213
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pure sensory neuropathy in primary Sjögren's syndrome. Longterm prospective followup and review of the literature.
    Font J; Ramos-Casals M; de la Red G; Pou A; Casanova A; García-Carrasco M; Cervera R; Molina JA; Valls J; Bové A; Ingelmo M; Graus F
    J Rheumatol; 2003 Jul; 30(7):1552-7. PubMed ID: 12858457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Abatacept treatment reduces disease activity in early primary Sjögren's syndrome (open-label proof of concept ASAP study).
    Meiners PM; Vissink A; Kroese FG; Spijkervet FK; Smitt-Kamminga NS; Abdulahad WH; Bulthuis-Kuiper J; Brouwer E; Arends S; Bootsma H
    Ann Rheum Dis; 2014 Jul; 73(7):1393-6. PubMed ID: 24473674
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pilot clinical trial of dehydroepiandrosterone (DHEA) versus placebo for Sjögren's syndrome.
    Pillemer SR; Brennan MT; Sankar V; Leakan RA; Smith JA; Grisius M; Ligier S; Radfar L; Kok MR; Kingman A; Fox PC
    Arthritis Rheum; 2004 Aug; 51(4):601-4. PubMed ID: 15334433
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduction of fatigue in Sjögren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study.
    Dass S; Bowman SJ; Vital EM; Ikeda K; Pease CT; Hamburger J; Richards A; Rauz S; Emery P
    Ann Rheum Dis; 2008 Nov; 67(11):1541-4. PubMed ID: 18276741
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased severity of lower urinary tract symptoms and daytime somnolence in primary Sjögren's syndrome.
    Walker J; Gordon T; Lester S; Downie-Doyle S; McEvoy D; Pile K; Waterman S; Rischmueller M
    J Rheumatol; 2003 Nov; 30(11):2406-12. PubMed ID: 14677185
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of sicca symptoms with hydroxychloroquine in patients with Sjogren's syndrome.
    Rihl M; Ulbricht K; Schmidt RE; Witte T
    Rheumatology (Oxford); 2009 Jul; 48(7):796-9. PubMed ID: 19433433
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atypical autoantibodies in patients with primary Sjögren syndrome: clinical characteristics and follow-up of 82 cases.
    Ramos-Casals M; Nardi N; Brito-Zerón P; Aguiló S; Gil V; Delgado G; Bové A; Font J
    Semin Arthritis Rheum; 2006 Apr; 35(5):312-21. PubMed ID: 16616154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adult heart block is associated with disease activity in primary Sjögren's syndrome.
    Lodde BM; Sankar V; Kok MR; Leakan RA; Tak PP; Pillemer SR
    Scand J Rheumatol; 2005; 34(5):383-6. PubMed ID: 16234186
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of Sjögren's syndrome in ambulatory patients according to the American-European Consensus Group criteria.
    Sánchez-Guerrero J; Pérez-Dosal MR; Cárdenas-Velázquez F; Pérez-Reguera A; Celis-Aguilar E; Soto-Rojas AE; Avila-Casado C
    Rheumatology (Oxford); 2005 Feb; 44(2):235-40. PubMed ID: 15509625
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of the Sjögren's Syndrome Responder Index, a data-driven composite endpoint for assessing treatment efficacy.
    Cornec D; Devauchelle-Pensec V; Mariette X; Jousse-Joulin S; Berthelot JM; Perdriger A; Puéchal X; Le Guern V; Sibilia J; Gottenberg JE; Chiche L; Hachulla E; Hatron PY; Goeb V; Hayem G; Morel J; Zarnitsky C; Dubost JJ; Seror R; Pers JO; Meiners PM; Vissink A; Bootsma H; Nowak E; Saraux A
    Rheumatology (Oxford); 2015 Sep; 54(9):1699-708. PubMed ID: 25957440
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.